Related Experiment Videos
Malignant familial long QT syndrome
Raghavan Subramanyan1, Poothirikovil Venugopalan
1Department of Pediatric Cardiology, Royal Hospital, Muscat, Sulanate of Oman. ragusha@omantel.net.om
Saudi Medical Journal
|June 19, 2002
Summary
Congenital long QT syndrome, a heart rhythm disorder, affects multiple family members with early, severe symptoms. Beta-blocker therapy proved effective in managing this inherited cardiac condition.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Congenital long QT syndrome (LQTS) is an inherited cardiac disorder affecting myocardial repolarization.
- LQTS is characterized by QT interval prolongation and risk of ventricular arrhythmias, leading to syncope, seizures, or sudden cardiac death.
Observation:
- A family with a high prevalence (11/16) of LQTS was identified.
- Affected individuals exhibited early symptom onset and a severe clinical course before diagnosis.
- A positive response to beta-blocker therapy was observed in the affected family members.
Findings:
- The genetic basis of LQTS involves defects in cardiac ion channel proteins.
- Diagnosis relies on QT interval prolongation (>0.45s) with suggestive symptoms or family history.
- Beta-adrenergic blocker therapy provides symptomatic relief for 80-85% of LQTS patients.
Implications:
- Identifying genetic factors in LQTS is crucial for early diagnosis and intervention.
- Beta-blocker therapy is a cornerstone treatment for managing LQTS symptoms.
- Avoiding triggers like intense exercise and emotional stress is vital for patients with LQTS.